Back to today’s briefing

Story perspectives

Innovative Inhaled Gene Therapy Trial for Cystic Fibrosis Launched

2/21/2025

25 3

Summary

Story summary

Researchers at Imperial College London have launched the LENTICLAIR 1 trial, testing BI 3720931, an innovative inhaled gene therapy for cystic fibrosis. Targeting patients unresponsive to current treatments, this groundbreaking trial will involve 36 participants across Europe, with hopes of enhancing lung function by early 2027.

1 of 1

Story summary

Researchers at Imperial College London have launched the LENTICLAIR 1 trial, testing BI 3720931, an innovative inhaled gene therapy for cystic fibrosis. Targeting patients unresponsive to current treatments, this groundbreaking trial will involve 36 participants across Europe, with hopes of enhancing lung function by early 2027.